Pre-existing and acquired drug resistance are major obstacles to the successful treatment of glioblastomas.
INTRODUCTION
The prognosis of patients with glioblastoma multiforme has not improved substantially during the last decades, and almost all patients die as a result of their disease. Current treatment approaches are based on radiation therapy and alkylating agent chemotherapy. O 6 -guanine alkylating agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ), are among the most widely used chemotherapeutics in treating glioblastomas because they can efficiently cross the blood-brain barrier. These agents have modest efficacy against glioblastomas.
1,2 A subset of glioblastoma patients demonstrates an initial response, lasting a few or several months and eventually leading to tumor recurrence.
One of the most prominent resistance mechanisms to alkylating agents includes O 6 -methylguanine DNA methyltransferase (MGMT), 3 which acts as a suicide enzyme by removing the methyl or chloroethyl damage at the O 6 -position of guanine. Epigenetic MGMT gene silencing via promoter hypermethylation, present in approximately 40% of cases, has been shown to predict outcome in glioblastoma patients treated with BCNU or TMZ. 4, 5 The growing awareness that resistance in human cancer is likely regulated by the coordinated alteration of molecular pathwaysthe changes described thus far for a limited number of known resistance genes. 3 Resistance of glioblastomas to alkylating agents such as BCNU and TMZ seems to follow a more complex pattern than simple dependence on MGMT levels.
3, [7] [8] [9] Excessive and prolonged activation of nuclear factor-B (NF-B) has been established as a principal mechanism of tumor chemoresistance, which is primarily mediated by its antiapoptotic activity. 10, 11 Some evidence also indicates a link between the NF-B pathway and resistance of glioblastoma cells to O 6 -alkylating agents, and suggests that inhibition of NF-B is a promising means to potentiate the cytotoxic effects of these agents. 12 The NF-B complex consists of a family of heterodimers, of which the p50/p65 heterodimer is the most abundant form. NF-B is active in the nucleus and is inhibited through its sequestration in the cytoplasm by the inhibitors of B (IBs), primarily through the interaction of IB proteins with p65. IB is a target of several well-characterized kinase cascades that activate IB kinases (IKKs), which phosphorylate IB and mark it for degradation via the ubiquination pathway, thereby allowing activation of NF-B. Activated NF-B translocates to the nucleus and binds DNA at B-binding motifs, which initiates gene transcription. Anticancer drugs are known to induce the expression of NF-B target genes through the direct activation of NF-B and the secondary production of NF-B activators.
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There is increasing recognition of the value of comprehensive approaches to the molecular characterization of biologic phenotypes such as drug resistance. We have here utilized an integrated model of glioblastoma resistance to O 6 -alkylating agents and genomics tools to globally explore molecular factors, cellular pathways, and functional interaction networks perturbed during the selection and evolution of drug resistance in glioblastoma cells. Our results highlight a key role of a cytoplasmic signaling cascade that activates NF-B in response to these agents. This pathway reveals the tumor necrosis factor-␣-induced protein 3 (TNFAIP3) gene as a factor associated with glioblastoma cell resistance.
values were deemed changed as compared with normal human reference DNA if they fell beyond the plus or minus three standard deviations (SDs) range (Ϯ 0.2135) of distribution of all signal-intensity ratios of control self-to-self hybridizations. For gene-by-gene integration of gene copy number and gene expression, copy numbers were reported as symmetric three-nearestgenomic-neighbors moving averages. 19 The TreeView software 20 was used to display gene expression and gene copy number ratios.
In the cell line model, 9,734 of 37,860 clones with expression in 80% of samples and whose expression levels differed by at least three-fold, in at least one sample, from their mean expression levels across all cell lines were included in downstream statistical analyses. One-class response significance analysis of microarrays (SAM), 21 which corrects for multiple testing by assigning a false discovery rate-based measure of significance, called q value, 22 was utilized after parental transformation of gene expression ratios of resistant sublines to identify genes overexpressed and underexpressed in all in vitro and in vivo BCNU-and TMZ-resistant sublines. Genes identified with q Ͻ 0.005 were deemed significant. Nonparametric t-test analysis was performed in R, 23 and was used to allocate additional statistical confidence to clones identified by SAM. Unsupervised hierarchical clustering was performed in Cluster, 20 and two-way average linkage clustering was applied, on the basis of Pearson correlation as a distance metric. Principal component analysis based on Pearson correlation was executed in MATLAB (The MathWorks, Natick, MA).
Gene Ontology and Functional Network Analysis
Analyses of gene ontology, canonical pathways, and functional networks were executed using tools from Ingenuity Pathways Analysis (Ingenuity Systems, Mountain View, CA), a Web-delivered application that enables the discovery, visualization and exploration of molecular interaction networks in gene expression data. The gene list identified by SAM, containing GenBank (National Institutes of Health, Bethesda, MD) accession numbers as clone identifiers as well as d-scores, was uploaded into the Ingenuity pathway analysis. Each clone identifier was mapped to its corresponding gene object in the Ingenuity Pathways knowledge base, which represents a proprietary ontology of 300,000 classes of biologic objects spanning genes, proteins, cells and cell components, anatomy, molecular and cellular processes, and small molecules. Semantically consistent pathway relationships are modeled based on a continual, formal extraction from the public domain literature and cover more than 10,300 human genes (www.ingenuity.com/products/pathways_knowledge .html). These mapped focus genes were then used as a starting point for generating biologic networks. A score was computed for each network according to the fit of the original set of significant genes. This score reflects the negative logarithm of the P value that indicates the likelihood of the focus genes in a network being found together as a result of random chance. Using a 99% confidence level, scores Ն 2 were considered significant. Significances for the enrichment of the genes in a network with particular biologic functions or canonical pathways were determined via right-tailed Fisher's exact test with ␣ ϭ .05 and the whole database as a reference set. The same computation was used for gene ontology analyses of the initial gene list.
Real-Time Reverse Transcription Polymerase Chain Reaction
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) reactions were performed with the ABI Prism 7900HT Sequence Detection System using SYBR GREEN PCR Master Mix (Applied Biosystems, Foster City, CA). Primers targeting the transcripts of TNFAIP3, NF-B inhibitor ␣ (NFKBIA), chromosome 8 open reading frame 4 (C8orf4) and leukemia inhibitory factor (LIF) genes and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene were designed with the Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and synthesized at the Stanford PAN Facility (for sequences, see Supplementary Table 1 , online only). Total RNA was reverse transcribed using the SuperScript first-strand synthesis system and SuperScript II (Invitrogen). Thermocycling for each PCR reaction was carried out in a final volume of 20 L containing 1 ng of cDNA, forward and reverse primers at 3 mol/L final concentration, and 1ϫ SYBR GREEN PCR Master Mix. After 10 minutes of initial denaturation at 95°C, the cycling conditions of 40 cycles consisted of denaturation at 95°C for 15 seconds, annealing at 55°C for 30 seconds, and elongation at 72°C for 30 seconds. All reactions were performed in triplicate. Dissociation curve analysis was performed after every run to confirm the primer specificity. Gene quantities were determined using standard curves, constructed by five serial dilutions of RT product of universal human reference RNA (Stratagene), and gene expression levels were reported as ratios of quantities of the target transcript and GAPDH as the reference transcript.
Immunoblotting
The light-enhanced chemiluminescence protocol was used for the detection of specific proteins from total cell lysates prepared using 1ϫ RIPA buffer (150 mmol/L NaCl, 10 
NF-B DNA-Binding Activity Assay
Nuclear protein extracts were prepared using the NucBuster Protein Extraction Kit (Novagen, Madison, WI) according to the manufacturer's instructions. DNA-binding activity of NF-B was assayed colorimetrically, utilizing the NoShift Transcription Factor Assay Kit and NoShift NF-B (p65) reagents (both Novagen) according to the manufacturer's instructions. To assess sequence-specific binding activity, 15 g of sample nuclear extract or 25 g of HeLa positive control nuclear extract were incubated with various combinations of biotinylated NF-B wild-type dsDNA, specific NF-B competitor dsDNA lacking biotin end labels, and nonspecific, nonbiontinylated dsDNA with a mutant NF-B consensus binding motif. Negative controls consisted of reactions performed in the absence of a binding sequence. HRP-conjugated goat antimouse immunoglobulin G, targeting an anti-NF-B (p65) mouse monoclonal antibody, was used as secondary antibody. All assays were performed in triplicate. Binding activity was measured via colorimetric absorbance at 450 nm on a ThermoMax multiwell spectrophotometer (Molecular Devices, Sunnyvale, CA) using 3,3Ј,5,5Ј-tetramethylbenzidine as substrate.
Survival Analysis
Overall survival was calculated from the date of tumor diagnosis until death or the last follow-up contact. Data were current as of January 1, 2005. At last follow-up 28% of patients were alive and 72% were dead. Patient subgroups were defined by unsupervised clustering of patients based on gene expression data of the resistance-associated transcripts revealed by SAM in the resistance model and with expression in Ͼ 75% of the tumor specimens. Actuarial survival curves between groups were estimated by the KaplanMeier product-limit method, and survival distributions between groups were compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed with overall survival as the dependent variable.
RESULTS

Resistance Signature of Glioblastoma Cells to O 6 -Alkylating Agents
One-class response SAM, following parental transformation, was used to identify gene expression patterns associated with resistance formation to O 6 -alkylating agents. A d-score was assigned to each gene on the basis of change in gene expression relative to the SD of repeated measurements. Permutations of the repeated measurements estimated the q value, a false discovery rate-based measure of significance. 21 The three sensitive parental sublines DI, LX, and ME were analyzed against the pool of 15 sublines with in vitro resistance to BCNU (DI-B and ME-B), in vivo resistance to BCNU (DIR, LXR, MER), combined in vivo/in vitro resistance to BCNU (DIR-B and MER-B), in vitro resistance to TMZ (LX-T, ME-T) and combined in vivo resistance to BCNU and in vitro resistance to TMZ (DIR-T, LXR-T, MER-T). This analysis revealed a set of 329 transcripts consistently overexpressed (78 clones, 23.7%) or underexpressed (251 clones, 76.3%) in the resistant versus the parental sublines (q Ͻ 0.005; Fig 1A; Supplementary Table 2, online only). The well-established resistance marker MGMT 3 was among the top-scoring overexpressed transcripts (q Ͻ 0.003). High-scoring underexpressed transcripts included the NF-B pathway-modulator TNFAIP3, which encodes the zinc finger protein A20
24
; the NF-B-inhibiting IB family member NFKBIA; the metastatic colon cancer-downregulated C8orf4
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; and the astrocyte differentiation-associated LIF 26 (q for all Ͻ .003). Figure  1A displays these clones ordered according to d-score significance. Nonparametric t testing in the context of multiple testing was performed to allocate additional confidence to this resistance signature. One hundred forty-one clones passed a P-value threshold Ͻ .01 (Supplementary Table 3 , online only). Although this analysis substantiated high significances for TNFAIP3 (P Ͻ .000001), C8orf4 (P Ͻ .000001), NFKBIA (P ϭ .000005), and LIF (P ϭ .000005) in the resistance phenotype, MGMT passed a P value filter Ͻ .05 only.
The strength and accuracy of this highest-confidence subset of 141 transcripts in predicting sensitive versus resistant phenotypes was evaluated by two-dimensional unsupervised average linkage cluster analysis after cell line-specific mean centering of the expression data. Gene expression levels of these transcripts separated hierarchical clustering samples into two groups on the basis of sensitivity phenotype (Figs 1B-1C). An unsupervised learning algorithm based on multidimensional scaling using the first three principal components confirmed the phenotype-specific separation of the sublines by the subset (Fig 1D) .
Genome-Wide Gene Copy Number Maps
Because gene copy number aberrations (CNAs) have a significant impact on gene expression patterns and also represent common mechanisms of gene activation and inactivation in drug resistance formation, we have mapped gene copy numbers in a high-resolution manner using the same cDNA microarray platform. Figure 2A reports the copy number profile for 33,587 clones mapped along the genome and mean filtered according to 5-mb windows moved across the chromosomes in 2.5-mb steps. Multiple resistance-associated CNAs, including both losses and gains, were found, with the extent of the chromosome involved in the CNAs differing for each chromosome. Although some areas of the profile were similar across most of the samples (eg, chromosome 9q33.2-q33.3), others showed differences based on the individual patient's tumor (eg, chromosome 13), or on whether the cells were from the primary or recurrent tumor (eg, chromosome 7q11.21-q31.31). The left panel of Figure 2A shows the recurrences frequencies of these changes in the resistant variants. Peak recurrences of chromosomal gains were noted for chromosomes 9p23-9p22.3, 10q21.1, 11q14.1, 14q23.2-q31.1, and 17p11.2, as were those of losses for chromosomes 1p35.2-p34.3, 8p23.2-p23.1, 9q33.2-q33.3, 22q11.1-q21.1, and Xp21.2-p21.1.
Integration of Gene Copy Number and Gene Expression Data
We then examined the effect of gene copy numbers on the expression of the 329 transcripts identified as resistance signature by SAM. For a gene-by-gene integration of copy numbers and expression, copy numbers were reported as symmetric three-nearestgenomic-neighbors moving average. 19 The data set was then filtered to include only those fluorescence ratios indicating genes that demonstrated at least Ϯ 2-fold changes in gene dosage in the resistant variants versus the corresponding sensitive parental sublines. 19 This analysis revealed a pervasive imprinting of aneuploidy on gene expression in a distinct subset of resistant sublines for 92 genes, 72 and 20 of which demonstrated losses and gains in copy number, respectively (Fig 2B) . Many of these genes with copy number-driven expression mapped to the recurrent resistance-associated chromosomal aberrations revealed in Figure 2A . C8orf4 and LIF were among the genes with reduced copy number in a subset of resistant sublines ( Figs 2B and 3A) , and MGMT was among those with increased copy number ( Figs 2B and 3C) . No difference in gene copy numbers of TNFAIP3 and NFKBIA were noted between the resistant and the sensitive sublines (Fig 3A) .
Gene Ontology, Biologic Pathway, and Network Analysis
To explore how the 329 transcripts identified by inferential statistics as part of a resistance-associated gene expression signature are related, we placed the genes in the context of present interactome knowledge, using Ingenuity Pathways Analysis tools. Initial gene ontology analysis revealed significant enrichment of the signature for genes involved in organismal survival (27.5%; P Ͻ .000003) and cell death (49.0%; P Ͻ .000005). Biologic pathway analysis revealed the NF-B canonical pathway as a significant molecular pathway in the data set (P ϭ .046). Network analysis based on predetermined knowledge about individually modeled relationships between genes identified seven highly significant, overlapping networks in the data set (Table 1 ; Fig 4A) . The top-scoring network, built around NF-B, displayed high-level functions in cell death, cellular compromise (stress), and organismal survival (Table 1) , and included several altered NF-B-interacting genes and NF-B pathway constituents and modulators such as TNFAIP3 and NFKBIA (Fig 4B) .
Exploration of the NF-B Candidate Pathway
Since our inferential statistical analysis and data from the literature 12 evidenced importance of the NF-B pathway in mediating resistance to O 6 -alkylating agents in glioblastoma cells, we searched the whole expression data set for alteration of additional members of this putative resistance pathway, applying a more liberal q-value threshold Ͻ 0.05 for the allocation of statistical significance. Using this threshold, the TNFAIP3 target RPA-interacting protein (RIP; Fig  3C) , 24 which has been implicated in NF-B-mediated cell responses to DNA damage, 27 was revealed to be significantly linked to the resistance phenotype (q ϭ 0.044). The recurrent overexpression of this gene was revealed to be related in part to gene copy number gains in the resistant glioblastoma genome (Fig 3C) . In addition, decreased expression of the IB family member NF-B inhibitor ⑀ (NFKBIE), which inhibits NF-B, was associated significantly with resistance formation at the same threshold level (q ϭ 0.027). Although not passing a q-value threshold Ͻ 0.05, expression alterations of additional NF-B pathway constituents were observed sporadically in our model. These included the underexpression of the gene encoding the TNFAIP3-interacting protein 1 (TNIP1; q ϭ 0.0975) in 50% of the resistant variants, a protein suggested to inhibit NF-B independent of its mutual interaction with TNFAIP3.
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Candidate Genes
Gene expression levels for the NF-B pathway genes TNFAIP3 and NFKBIA were confirmed by real-time RT-PCR. The relative expression of the two transcripts C8orf4 and LIF, deemed biologically interesting because of their highly significant association with the resistance phenotype, was also confirmed by real-time RT-PCR. C8orf4, which is downregulated in metastatic colon cancer, has been implicated in colon cell differentiation and transforming growth factor ␤-induced apoptosis. 25 The neuropoietic cytokine family member LIF regulates gliogenesis 29 and promotes differentiation of astrocytes. 26, 30 Normally, this gene is expressed in glioma cells 31 and mediates a growth inhibitory effect in these cells.
32 Figure 3A correlates the expression levels of these four genes revealed by the microarray and the real-time RT-PCR analyses, and also indicates the gene copy number profiles for these genes. There was high concordance between both analyses in individual sublines (Fig 3A) , as well as when the mean transcription levels of all resistant sublines normalized to their corresponding parental cells and their spreads were compared (Fig 3B) . Figure 3C interfaces gene expression and copy numbers for RIP and MGMT, indicating the relationship of RIP gene dosage to gene expression in the DI/DIR cell lines, but not LX/LXR and ME/MER. MGMT gene dosage correlates with expression in some, but not all of the cell lines examined.
Correlation of TNFAIP3 Protein and Gene Expression
Because our integrated large-scale screening and inferential statistical approach for resistance factors had highlighted a potentially important role of the NF-B pathway modulator TNFAIP3 in the resistance of glioblastoma cells to O 6 -alkylating agents, we examined whether the reduced expression of the TNFAIP3 transcript in the resistant cells may be reflected by reduced expression of the cognate protein product A20. Figure 5B shows a representative immunoblot in ME cell lines. Figure 5A indicates that the level of A20 protein expression in these cell lines normalized to loading controls. A substantial reduction in protein expression in all resistant variants compared with the sensitive parental subline was noted. Figure 5A also correlates TNFAIP3 protein and gene expression in these cells. In each cell line, the levels of protein product closely mirrored the expression of the corresponding transcript as determined using real-time RT-PCR.
DNA-Binding Activity of NF-B in Sensitive Versus Resistant Cells
Because the presumed functional consequence of downregulation of TNFAIP3 transcript and protein is increased NF-B pathway activation with resulting nuclear translocation and DNA binding of NF-B, we then assessed the NF-B DNA-complexing activity in sensitive versus resistant cells. NF-B activation was assayed by the binding of NF-B to oligonucleotides containing the consensus binding site. Figure 5C shows a competitive analysis of NF-B DNAbinding activity in parental ME cells and resistant ME-B, MER, and MER-B cells. Nuclear extract from HeLa cells stimulated with TNF-␣ was used as a positive control. 33 To assess sequence-specific binding activity, nuclear extracts were incubated with NF-B wild-type DNA, with or without either specific NF-B competitor DNA or nonspecific mutant NF-B consensus-binding motif. When incubated with wildtype DNA alone, significantly increased NF-B DNA binding was observed in the resistant variants compared with the parental subline (P Ͻ .001). Specific competitor DNA significantly reduced the binding activity in all cell lines (P Ͻ .001), confirming sequence-specificity of the assay for NF-B binding, but binding activity remained comparable to wild-type DNA alone when wild-type DNA was coincubated with the nonspecific, mutant binding motif (Fig 5C) . The NF-B DNA-binding activity related directly to the level of expression of TNFAIP3 transcript and A20 protein; those cells with most reduction in TNFAIP3 and A20 were those that demonstrated the highest NF-B DNA-complexing activity (Fig 5) .
Outcome Prediction Model Based On Resistance Signature
We evaluated the clinical impact of our resistance signature in an independent cohort of glioblastomas commonly treated with O 6 -alkylating agents. In order to create a model for predicting survival and response in glioblastomas, we queried the expression status of the 329-transcript resistance signature derived from the cell line model in the gene expression profiles of 31 glioblastomas from a different institution (Stanford University Medical Center, Stanford, CA). One hundred seventy-two transcripts were expressed in at least 75% of the tumors (Supplementary Table 4 , online only). Unsupervised hierarchical clustering of the tumors based on these transcripts, applying two-way average linkage clustering based on Pearson correlation as a distance metric, resulted in two major tumor subgroups (group 1, 12 patients; group 2, 19 patients) with distinct gene expression signatures (Fig 6A) . Highly correlated expression behavior was observed for two major gene clusters (Fig 6A) . One of these clusters demonstrated persistent overexpression in group 1 and persistent underexpression in group 2, and included two coclustering transcripts of TNFAIP3 and one transcript each of NFKBIA, C8orf4, and LIF. The other gene cluster showed overexpression in a subset of tumors in group 2 and included the MGMT transcript. On the basis of these gene expression signatures, we labeled group 1 as a potentially favorable tumor group and group 2 as an unfavorable tumor group. Actuarial survival analysis revealed a significant difference in survival between the two groups (log-rank P ϭ .037; Fig 6C) . The overall survival rates at 2 years in groups 1 and 2 were 0.53 and 0.09, and the median survival times were 814 and 412 days, respectively (Fig 6B) .
Because a smaller number of genes would make the predictive model more practical, we sought to reduce the number of genes in the predictor. A supervised approach via two-class, unpaired SAM was used to identify those genes that were driving the clustering of the tumors (Supplementary Table 5 , online only). A gene signature based on the top-10 ranking transcripts that included TNFAIP3 (rank 4) and C8orf 4 (rank 8) was sufficient to drive the unsupervised tumor grouping into two main classes (class error rate, 0.03) NOTE. Boldfacing indicates genes of the test set that were underexpressed in the resistant cells. Genes that were overexpressed in the resistant cells are indicated with paragraph symbol. Genes in plain type without footnotes are nonfocus genes that were not altered in expression in the test set.
‫ء‬
No. of genes identified as part of the test set mapping to the network. †Reflects the negative logarithm of the P value that indicates the likelihood of the focus genes in a network being found together as a result of random chance (99% confidence level; scores Ն 2 were considered significant).
‡No. of genes significantly associated with the corresponding high-level function. §Range of signifcances of the associated genes for the high-level function (␣ ϭ .05). ¶Genes of the test set that were overexpressed in the resistant cells. and was associated significantly with outcome according to loglikelihood estimate (P ϭ .016; Fig 6D) . All but one transcript (␤1, 4-N-acetylgalactosaminyltransferases IV [␤4GalNAc-T4]; rank 6) demonstrated reduced expression in the unfavorable tumor subgroup. Because a focused number of genes would be particularly amenable to future target modulation we optimized the model by further minimizing the number of predictive genes on the basis of SAM ranking. Hierarchical clustering according to the top four transcripts (CD44 antigen [CD44], F-box protein 32 [FBXO32], syndecan 1 [SDC1], and TNFAIP3) revealed two major tumor subgroups (14 v 17 tumors), which demonstrated a significantly different outcome in actuarial survival analysis (log-rank P ϭ .007; Fig 6E) . Because of the apparent difference in the expression of these genes between the two groups, we performed a Cox proportional hazards regression analysis of the individual genes, with overall survival as dependent variable. TNFAIP3 and CD44 were associated significantly with outcome when considered as individual continuous variables (univariate P ϭ .028 and .032, respectively). We then examined the combined predictive potential of all four genes, using the average expression of the genes weighted for their relative predictive contribution as indicated by the individual Cox scores. As a continuous variable, the combined predictive model performed better in outcome prognostication compared with the individual genes (univariate P ϭ .022). This model remained significantly associated with patient outcome when taking into account patient age (multivariate P ϭ .025), the most important clinical prognosticator for glioblastomas.
Finally, we examined how the model would perform as a class. We used a schema based on median gene expression to subtype the tumors. Here, the expression of each of the four genes was labeled either high or low based on the median level of all tumors and the number of calls was counted. This approach generated a simplified gene expression profile for each tumor, represented by an integer between 0 and 4 for the number of low-and high-expression calls. If a tumor had at least three low calls, it was classified as potentially unfavorable (group 2); if there were one or fewer low calls, the tumor was classified as favorable (group 1); if a tumor had an equal number of low and high calls, the patient's prognosis was not inferred on the basis of the expression data of the four genes ("noninformative" group 3). Such stratification revealed 14 tumors each to fall into groups 1 and 2, and three tumors into group 3. Actuarial survival analysis disclosed a strikingly different outcome between groups 1and 2 (log-rank P ϭ .026), with favorable tumors demonstrating a comparably good prognosis (Fig 6F) .
DISCUSSION
We have identified a distinct genomic signature shared by glioblastoma cells selected for resistance to O 6 -alkylating agents under in vitro and in vivo conditions. Our results highlight the involvement of a cellular pathway of NF-B-mediated resistance to these agents in glioblastoma cells. The contribution of NF-B to anticancer drug resistance has been described in various in vitro and in vivo resistance models. 10 The antiapoptotic activity of NF-B appears to be the most important mode of action mediating the resistance and pro-survival effects of this gene in cancer cells. 10, 34 Genotoxic stress resulting from the exposure of tumor cells to O 6 -alkylating agents causes DNA damage and leads to the initiation of apoptosis. NF-B activation abrogates the apoptosis signal in response to these agents. 10 Antagonism of NF-B in malignant gliomas has been shown to render glioma cells more susceptible to BCNU via increased apoptosis, 12 but the DNA damage-induced signaling pathway upstream of IB has not been identified in these cells.
We have found alterations in several NF-B pathway members in glioblastoma cells, which may act synergistically in activating NF-B during resistance formation to O 6 -alkylating agents. The most significant link to resistance to these agents within the NF-B pathway was revealed for TNFAIP3. The consistent downregulation of this gene in our resistance models suggests a potentially important role of this gene in the development of resistance to O 6 -alkylating agents in glioblastoma cells. Protein levels of TNFAIP3 related directly to the expression of the corresponding transcript, as well as to the levels of NF-B-DNA-binding activity of the cells.
The zinc finger protein TNFAIP3 35 is a potent inhibitor of NF-B signaling. 36 Its mechanism of action involves the cooperative activity of its two ubiquitin-editing domains. 24 The amino-terminal 
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Optimized and simplified predictive model based on the weighted expression of four resistance-associated genes. According to Cox proportional hazards regression analysis, P ϭ .022 for the model as a continuous variable, and log-rank P ϭ .007 for the model as a class based on the two major subgroups defined by unsupervised hierarchical clustering. (F) Partitioning of the tumors into two discrete subgroups (group 1, favorable; group 2, unfavorable) by the four-gene predictor model (see Outcome Prediction Model Based On Resistance Signature section for details; log-rankdomain of TNFAIP3, 37 removes lysine-63-linked ubiquitin chains from RIP. 24 The carboxy-terminal domain, composed of seven C 2 /C 2 zinc fingers, 36 then functions as an ubiquitin ligase by polyubiquitinating RIP with K48-linked ubiquitin chains, thereby targeting RIP for proteasomal degradation. 24 In addition to consistent downregulation of TNFAIP3 in resistant glioblastoma cells, which frees RIP, we also found a significant upregulation (q Ͻ 0.05) of RIP in these cells. This observation supports a cooperative or reciprocal molecular mechanism for these two genes in the resistant phenotype. RIP, which complexes with IB, has been reported to have an essential role in DNA damage-induced NF-B activation, but not in UV-induced NF-B activation.
27 RIP-mediated NF-B activation by drug-andirradiation-inducedDNAdamageisnotmediatedbyautocrine or tumor necrosis factor (TNF) receptor 1 signaling. In line with recent evidence indicating that TNFAIP3 is critical for the regulation of TNFindependent signals that lead to termination of NF-B activity, 38 our data provide evidence for an upstream extension of a RIP-mediated signaling cascade that augments NF-B-induced resistance in glioblastoma cells to DNA-alkylating agents. Although the initiation point of this resistance signal remains ambiguous, our data support a model that extends its cytoplasmic pathway to TNFAIP3. We therefore propose a dual mechanism that may synergistically foster the activation of NF-B by these agents. On receiving the nuclear signal in response to DNA damage, upregulation of RIP has been hypothesized to initiate the cytoplasmic signaling that activates NF-B.
27 RIP action and its complexing with IB may be enabled and ameliorated by downregulation of TNFAIP3 in the resistant cells, which under normal cell conditions obscures RIP by targeting it to proteasomal degradation. Functional validation will be needed to confirm this candidate resistance pathway in glioblastomas.
Our resistance signature-based outcome predictor model, derived from the cell lines, enabled us to subcategorize an independent cohort of glioblastomas commonly treated with O 6 -alkylating agents into two major groups with apparently different outcomes. On the basis of this link, we reasoned that the observed difference in survival may have been the result of distinct response characteristics of these tumors to therapy rather than different biologic tumor behavior. The inclusionofmoregenesmaymakeourpredictivemodelperformbetterin independent validation analyses, but a smaller number of genes would make the model more practical and also amenable to future target modulation approaches. We have therefore reduced our resistance signature to a minimal number of genes for use in constructing a predictive model. We have shown that measurement of the weighted expression of four resistance-related genes was sufficient in predicting patient outcome. This optimized predictor, which included the four transcripts SDC1, CD44, FBXO32, and TNFAIP3, was able to partition glioblastomas into two subgroups according to their survival. The identification of TNFAIP3 as part of this predictor corresponds to its significant association with both resistance formation and NF-B activation in our in vitro and in vivo cell models. It is supported as well by strong evidence for a link between NF-B and glioblastoma cell survival 39 and glioblastoma cell resistance to cytotoxic therapy.
12,40
We have found reduced expression for all four genes associated with poor patient outcome. In line with our results, loss of SDC1, a transmembrane type I heparan sulfate proteoglycan and member of the syndecan proteoglycan family, has been linked to unfavorable prognosis of various human malignancies, including squamous cell carcinoma of the head and neck, 41 laryngeal cancer, 42 poorly differentiated non-small-cell lung carcinoma, 43,44 hepatocellular carcinoma with high metastatic potential, 45 and gastric cancer. 46 In addition, SDC1 has been reported as a predictor of chemotherapy efficacy in oral squamous cell carcinoma, with decreased expression in response to cytostatic treatment indicating a poor prognosis. 47 CD44 has various functions in cell-cell and cell-matrix interactions. Expression of this cell-surface glycoprotein has been linked to increased survival in node-negative, invasive breast cancer, 48 and to indicate favorable prognosis in epithelial ovarian cancer. 49 Lack of CD44 expression is also a highly significant factor of poor outcome in neuroblastoma. 50 CD44v6 has been shown to predict responses to treatment in advanced colorectal cancer. 51 FBXO32, 52 which constitutes a potential substrate-recognition component of the cell cycle-regulating SKP1-cullin-F-box ubiquitin protein ligase complex and functions in phosphorylation-dependent ubiquitination, 53, 54 has not been associated with tumor prognosis and drug resistance so far. ␤4GalNAc-T4, which is involved in protein glycosylation, 55 was the only high-ranking transcript for which increased expression was associated with unfavorable outcome. Although the role of ␤4GalNAc-T4 in drug resistance remains enigmatic, altered protein glycosylation has been implicated in tumorigenesis. 56 A limitation of our study, however, was the relatively small sample size and the not completely uniform treatment of our patients. Assessment of our predictor in a larger, standardized patient population will be necessary to ultimately assign outcome significance to these genes in glioblastomas, and to refine parameters for risk-based stratification.
In summary, our results suggest a role of a cellular pathway that leads to NF-B activation during the emergence of acquired resistance to O 6 -alkylating agents in glioblastoma cells. Although our data indicate the alteration of various members of the NF-B canonical pathway, the endogenous NF-B inhibitor TNFAIP3 was linked most significantly to the resistance phenotype. TNFAIP3 gene as well as protein expression mirrored the level of NF-B activation in these cells. Though it remains unclear how the DNA damage response is linked to the cytoplasm, downregulation of TNFAIP3 may promote the initiation of an RIP-dependent signaling cascade that mediates NF-B-induced cell survival. TNFAIP3 related significantly to patient outcome in a cohort of glioblastomas, and was a member of an optimized four-gene outcome predictor that enabled the subcategorization of these tumors. These observations raise the hope for an amenable target to modulate NF-Bmediated resistance in glioblastomas cells, with the ultimate goal of increasing the efficacy of chemotherapy in patients harboring these challenging malignancies.
